Literature DB >> 11398171

Phage display selection of peptides that affect prostate carcinoma cells attachment and invasion.

V I Romanov1, D B Durand, V A Petrenko.   

Abstract

BACKGROUND: Prostate cancer-specific proteins must be identified to serve as diagnostic and prognostic markers. Cell surface proteins are especially important, because they have potential utility as diagnostic markers and therapeutic targets. Identification of ligands for these proteins will allow use of these ligands as diagnostic and therapeutic tools and permit the investigation of receptor function. We performed a search for peptide ligands to prostate cancer cell-specific receptors.
METHODS: Peptide phage display library was used to isolate specific ligands to LNCaP prostate carcinoma cells receptors. Selected phage and cognate peptides were investigated for their cancer-related functions, such as the ability to interfere with cell adhesion, spreading, motility, and invasion.
RESULTS: Phage designated pg35, blocked spreading of LNCaP cells and their derivatives C4-2 and C4-2b. Cognate peptide did not inhibit spreading, but incubation of C4-2 and C4-2b cells with cognate peptide increased their affinity for endothelial cells and invasiveness. In addition, the peptide activates matrix metalloproteinase (MMP)-2 and 9 in C4-2 and C4-2b cells.
CONCLUSIONS: These results indicate that identified ligands may play a role in tumorigenicity and metastatic transformation of prostate cancer. To our knowledge, this is the first identification of a functional cancer-specific peptide ligand using the phage display approach. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11398171     DOI: 10.1002/pros.1068

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  22 in total

1.  Selection of muscle-binding peptides from context-specific peptide-presenting phage libraries for adenoviral vector targeting.

Authors:  Debadyuti Ghosh; Michael A Barry
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

2.  Landscape Phage as a Molecular Recognition Interface for Detection Devices.

Authors:  Valery A Petrenko
Journal:  Microelectronics J       Date:  2008-02

Review 3.  Combinatorial peptide libraries: mining for cell-binding peptides.

Authors:  Bethany Powell Gray; Kathlynn C Brown
Journal:  Chem Rev       Date:  2013-12-03       Impact factor: 60.622

4.  Landscape phage ligands for PC3 prostate carcinoma cells.

Authors:  P K Jayanna; D Bedi; P Deinnocentes; R C Bird; V A Petrenko
Journal:  Protein Eng Des Sel       Date:  2010-02-25       Impact factor: 1.650

5.  Inhibitory effects of a specific phage-displayed peptide on high peritoneal metastasis of gastric cancer.

Authors:  Feihu Bai; Jie Liang; Jun Wang; Yongquan Shi; Kedong Zhang; Shuhui Liang; Liu Hong; Huihong Zhai; Yuanyuan Lu; Yu Han; Fang Yin; Kaichun Wu; Daiming Fan
Journal:  J Mol Med (Berl)       Date:  2006-10-17       Impact factor: 4.599

Review 6.  Techniques for molecular imaging probe design.

Authors:  Fred Reynolds; Kimberly A Kelly
Journal:  Mol Imaging       Date:  2011-12       Impact factor: 4.488

7.  In vivo selection of phage for the optical imaging of PC-3 human prostate carcinoma in mice.

Authors:  Jessica R Newton; Kimberly A Kelly; Umar Mahmood; Ralph Weissleder; Susan L Deutscher
Journal:  Neoplasia       Date:  2006-09       Impact factor: 5.715

Review 8.  Phage display in molecular imaging and diagnosis of cancer.

Authors:  Susan L Deutscher
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

9.  Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion.

Authors:  Fraser Conrad; Xiaodong Zhu; Xin Zhang; Robert J Chalkley; Alma L Burlingame; James D Marks; Bin Liu
Journal:  J Mol Med (Berl)       Date:  2009-02-14       Impact factor: 4.599

10.  Targeted delivery of siRNA into breast cancer cells via phage fusion proteins.

Authors:  Deepa Bedi; James W Gillespie; Vasily A Petrenko; Andreas Ebner; Michael Leitner; Peter Hinterdorfer; Valery A Petrenko
Journal:  Mol Pharm       Date:  2013-01-08       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.